Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology Brothers
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Modafinil use curtails severe, treatment-related fatigue

November 1, 2008
By Susan London
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 11
Volume 17
Issue 11

About 80% of cancer patients undergoing chemotherapy, and 89% of those who undergo radiation therapy, experience fatigue during their treatment. But about 30% of cancer patients continue to feel fatigued for years aft er treatment. A phase III study demonstrated that the eugeroic agent modafinil (Provigil) reduces severe fatigue and sleepiness among cancer patients undergoing chemotherapy.

ABSTRACT: Sleepiness decreased, depression was unchanged by narcolepsy drug in this phase III trial.

About 80% of cancer patients undergoing chemotherapy, and 89% of those who undergo radiation therapy, experience fatigue during their treatment. But about 30% of cancer patients continue to feel fatigued for years after treatment. A phase III study demonstrated that the eugeroic agent modafinil (Provigil) reduces severe fatigue and sleepiness among cancer patients undergoing chemotherapy.

Gary R. Morrow, PhD, associate director for community research at the University of Rochester Cancer Center, led U2901, a randomized, double-blind phase III trial in cancer patients starting chemotherapy at affiliates of the center’s Community Clinical Oncology Program and who had a fatigue level exceeding 1 on the 10-point Brief Fatigue Inventory at baseline (cycle 2).

The 642 patients were assigned to daily placebo or 200 mg of modafinil, a drug that is currently approved for the treatment of narcolepsy and other sleeprelated conditions, and that has stimulatory properties but no peripheral effects or potential for addiction.

Treatment was started on the tenth day of chemotherapy cycle 2 and ended after the seventh day of cycle 4. Fatigue, sleepiness, and depression were assessed from patient reports, and differences between groups at cycle 4 were compared, adjusting for values at baseline, according to Dr. Morrow (ASCO 2008 abstract 9512).

The majority of the patients had breast or alimentary cancers. At baseline, 11% of the patients had mild fatigue (a score of 0-4 on the inventory), 17% had moderate fatigue (a score of 5 or 6), and 73% had severe fatigue (a score of 7-10).

At cycle 4, compared with their counterparts in the placebo group, patients in the modafinil group had significantly less sleepiness on the Epworth Sleepiness Scale (http://epworthsleepinessscale.com/).

This result provided reassurance that the drug does was adequate, Dr. Morrow said. In addition, the observed changes had a physiologic basis.

Modafinil significantly reduced fatigue relative to placebo in the trial population overall. Further analysis by the group indicated that the eff ect varied according to the baseline level of fatigue, Dr. Morrow reported.

Patients with severe fatigue had significantly less fatigue when treated with modafinil compared with placebo.

However, those with mild fatigue or moderate fatigue did not report any change in their status, he said.

Dealing with depression

Despite positive results in fatigue, modafinil had no effect on depression, suggesting that the latter condition will require separate treatment.

“The simple fact of the matter is that we don’t know what causes cancer-related fatigue any more than we know what causes fatigue in general,” Dr. Morrow said.

He cited research conducted by his team that showed the antidepressant paroxetine hydrochloride (Paxil) improved depression but did not alleviate fatigue, even in various subgroups (Breast Cancer Res Treat 89:243-249, 2005).

The trial’s findings have implications in terms of the etiology of cancer-related fatigue and its treatment, according to Dr. Morrow.

“Paxil changed depression but not fatigue. Modafi nil changed severe fatigue but not depression,” he commented. “Ergo, it is quite unlikely they are the same thing.”

 

 

 

 

 

 

The Vantage Point on this article can be found here:
Would a higher dose make a difference?

Articles in this issue

Move to abandon anthracyclines in adjuvant breast cancer care is premature
Elaine Jaffe: At the forefront of clinical lymphoma biology
Clinical trials struggle to recruit, retain patients
Global financial woes threaten new UK radiotherapy centers
UK health service urges drug cost cuts
Birth length of at least 50 cm may bump up breast ca risk
Obama, NCCN win endorsements in online poll surveys
Colonoscopy proves cost-effective in young patients
Philips Healthcare extends contract for image-guided oncology
US Oncology teams with RTOG to boost trial enrollment
Court finds Roche infringed on Amgen’s erythropoietin patents
Advanced colon ca: Is sequential treatment preferred?
Infusion confusion: Quick fixes for keeping reimbursement on track
Would a higher dose make a difference?
Cancer film festival salutes international documentaries

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Event-free survival benefit was observed among BCG-naïve patients with carcinoma in situ undergoing treatment with sasanlimab plus BCG.
Specialties including neurosurgery, radiation oncology, and neuro-rehabilitation all play a notable role in the care of patients with brain tumors.
Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Related Content

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.

FDA Approves Perioperative Pembrolizumab Plus Radiation in HNSCC

Russ Conroy
June 12th 2025
Article

Data from the phase 3 KEYNOTE-689 trial support the approval of the pembrolizumab-based regimen in this locally advanced HNSCC population.


An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.

CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025

Rahul Banerjee, MD, FACP;Taha Al-Juhaishi, MD;Muhammad Salman Faisal, MD
June 9th 2025
Podcast

An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.


The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.

Revumenib Plus Azacitidine/Venetoclax Appears Safe in Older NPM1/KMT2Ar AML

Ariana Pelosci
June 12th 2025
Article

The VIALE-A trial showed high activity with revumenib plus azacitidine and venetoclax for patients with NPM1m/KMT2Ar AML.


Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Sharpening the Prostate Cancer Toolkit: Practical Insights on PSMA Imaging

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD;Mike Lattanzi, MD;Damian N. Sorce, MD
June 5th 2025
Podcast

Experts weigh in on the practical applications of PSMA PET imaging


FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

FDA Grants Fast Track Designation to RAD101 Imaging for Brain Metastases

Tim Cortese
June 12th 2025
Article

The developer plans to share topline results for RAD101 in various solid tumors from the supporting phase 2b trial in the second half of 2025.


In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

Roman Fabbricatore
June 12th 2025
Article

In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.